β-blockers in Heart Failure

Sustained release metoprolol succinate was studied in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). All-cause mortality (primary endpoint) was significantly reduced with the extended-release formulation of metoprolol succinate (target dose 200 mg once daily) compared to placebo; mortality was reported in 7.3% of patients randomized to metoprolol ... ................
................